To report aortic root geometry by echocardiography in a large population of healthy, asymptomatic aortic stenosis (AS) patients in relation to current vendor-specified requirements for transcatheter aortic valve implantation (TAVI).
Introduction
Assessment of aortic root dimensions by transthoracic echocardiography (TTE) is routinely used in the clinical setting, in particular in evaluation of patients with aortic valve or aortic root disease including those evaluated for transcatheter aortic valve implantation (TAVI). 1, 2 Currently TAVI is regarded an alternative treatment for patients with aortic stenosis (AS) who are not accepted for conventional valve replacement due to unacceptable high perioperative risk, 3 -5 but this may potentially change as long-term results and implications of TAVI treatment become known. At present, it is unknown how often the aortic root size requirements for TAVI are met in more healthy groups of AS patients. Aortic root anatomy in relation to TAVI prosthesis selection and implantation has previously been reported from small studies using different imaging modalities including transoesophageal and TTE, angiography, and multislice computer tomography. 2, 6, 7 However, the sinus of Valsalva height, another important measure in the evaluation for TAVI, has so far only been addressed by TTE in healthy subjects. 1,7 -9 Thus, the aim of the present analysis was to describe aortic root geometry by TTE in a large population of healthy asymptomatic AS patients and relate these findings to current requirements for TAVI.
Methods
The present analysis was prospectively planned within the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study that enrolled 1873 patients with asymptomatic AS, defined by TTE as aortic valve thickening and peak transaortic velocity ≥2.5 and ≤4.0 m/s. Patients were randomized from 2001 to 2007 in 173 European study centres to ≥4-year placebo controlled combined treatment with Simvastatin 40 mg and Ezetimibe 10 mg daily. 10, 11 The present study population comprises the 1481 (79.1%) patients recruited in the study in whom complete aortic root geometry including aortic diameter at four levels (annular, sinus of Valsalva, sinotubular junction, and supracoronary) as well as the sinus of Valsalva height could be measured on the baseline echocardiogram. Baseline echocardiograms were obtained following a standardized protocol and sent for expert interpretation at the Echocardiographic Core Laboratory at Haukeland University Hospital, Bergen, Norway. 12 Quantitative echocardiography was performed following the joint European Association and American Society of Echocardiography guidelines. 13 The inner aortic diameter was measured at four levels:
annulus, sinus of Valsalva, sinotubular junction, and supracoronary 1 cm distal to the sinotubular junction. The annular diameter was measured in mid-systole and diameters of the aortic root in end-diastole. 14 The height of the sinus of Valsalva was measured in end-diastole as the aortic annulo-sinotubular junction distance. 7 The effective aortic valve area was calculated using the continuity equation and indexed for body surface area. Aortic pressure recovery was estimated at the level of the sinotubular junction, and pressure recovery adjusted aortic valve area index (AVAI), i.e. energy loss index (ELI), was calculated as previously published. 15 Severe AS was diagnosed as AVAI and ELI ≤ 8 Data are presented as mean + SD. Groups were compared by Student's unpaired t-tests. Univariate correlations were evaluated by Pearson's correlation coefficients. Covariates of sinus height were identified in multiple linear regression analysis with collinearity diagnostic tools. Reproducibility of the measurement of sinus of Valsalva height was assessed from repeat measurements in the last 100 patients recruited in the SEAS study. A P-value of ,0.05 was regarded statistically significant.
Results
In the total study population, the annular diameter could be measured in 94.2%, sinus of Valsalva diameter in 85.1%, sinotubular junction and sinus of Valsalva height in 85.1% and 85.0%, respectively, and supracoronary aortic diameter in 79.1%. A new, repeat measurement of sinus of Valsalva height was done by the same reader in the last 100 study patients on digitally stored echocardiographic images in the SEAS echocardiography core laboratory blinded to results from the initial analysis. Reproducibility was excellent with an intraclass correlation coefficient of 0.987 (95% confidence interval 0.981 -0.992) (Figure 1) .
Clinical characteristics and echocardiographic findings in the study population are reported in Tables 1 and 2, respectively. Severe AS by AVAI was present in 643 (44.3%) of the patients and severe AS by ELI was present in 350 (24.1%). The range of the aortic annular diameter was 1.41-3.21 cm and that of the sinus of Valsava height 0.71-3.19 cm. The ratio of height to width of sinus of Valsalva was 1:2 ( Figure 2 ). The prevalence of bicuspid aortic valves was 5.1%, and more than mild aortic or mitral regurgitation was present in 0.8% as a consequence of the SEAS inclusion criteria.
Larger sinus of Valsalva diameter and height were both weakly, but statistically significant associated with larger aortic valve area, while no associations were found with other measures of AS severity, including peak aortic jet velocity, mean transaortic gradient, and ELI ( Table 3) . In multivariate analysis only larger sinus of Valsalva diameter was independently associated with larger aortic valve area ( Table 4) .
Patient body size was an important covariate of aortic root size, and older age was associated with smaller sinus of Valsalva diameter in univariate analysis ( Table 3) . In multivariate linear regression analysis, larger sinus of Valsalva height was associated with larger sinus of Valsalva diameter, lower LV ejection fraction, and smaller supracoronary aortic diameter (all P , 0.05, Table 4 ). No independent association was found with patient age, gender, body height, serum creatinine, or aortic valve area in this model. In a similar model, larger sinus of Valsalva diameter was associated with male gender and larger body height, sinus of Valsalva height, and supracoronary aortic diameter, and with lower LV ejection fraction, systolic blood pressure, and aortic valve area (all P , 0.05, Table 4 ). No independent association was found with patient age and serum creatinine in this model. Replacing body height with body surface area in the models did not change the results (data not shown).
The required annular diameter for the CoreValve prosthesis was met in 61.9% and for the Edwards-Sapien prosthesis in 66.9% of patients ( Table 5 ). It was found that 40.0% of women and 14.3% of men had too small and 0.3% of women and 5.6% of men had too large aortic diameters, respectively, to allow implantation of a CoreValve prosthesis (both P , 0.01). Similarly, the Edwards-Sapien prostheses would be unsuitable for 9.5% of women and 2.2% of men due to too small and 3.8% of women and 24.0% of men due to too large annular diameters, respectively (both P , 0.001). Overall, 78.2% (73.5% women vs. 81.3% men, P , 0.001) had aortic annular dimensions within current vendor-specified requirements. The sinus of Valsalva height requirement for different prostheses was met in 66.8-91.4% (Table 5) . Overall, 77.7% of patients (73.3% women vs. 80.6% men, P , 0.001) met combined aortic root requirements for the annular diameter and the sinus of Valsalva height for any of the current available transcatheter aortic valve prostheses. Comparing the group of patients who met TAVI requirements with that of patients those who did not, the latter included Aortic root geometry in aortic stenosis patients more women and patients with lower body height and weight and smaller aortic root dimensions (all P , 0.05; Table 6 ).
Discussion
This study is the first to report aortic root geometry by TTE in a large population of AS patients, focusing on the feasibility for TAVI based on vendor-specified requirements for the annular diameter and the sinus of Valsalva height. Although TAVI treatment is only indicated in patients with severe symptomatic AS who cannot be offered conventional aortic valve replacement, this may potentially change if favourable long-term results and implications of TAVI are documented. The current study population is a cohort at risk for future aortic valve replacement, and how current vendor-specified requirements for aortic root dimension covers the observed variation in aortic root geometry in our population is therefore of interest.
The present results demonstrate that the sinus of Valsalva height could be measured with excellent reproducibility by TTE in 85% of patients participating in the SEAS study. However, complete aortic root geometry assessment was only possible in 79.1% of SEAS patients, mainly as a result of the supracoronary aortic level not being adequately visualized. The results demonstrate that while aortic root geometry fulfils vendor requirements for TAVI in the large majority of AS patients, women with small aortic roots remain a therapeutic challenge. This observation is in line with the previous findings that body size is the predominant determinator of aortic annulus, sinus of Valsalva diameter, and sinotubular junction, whereas age is the most important predictor of aortic dimension at the supracoronary level in the normal population. 16 Of note, the present study did not find a strong relation between AS severity and aortic root size, confirming previous publications in which post-stenotic aortic dilation was not related to the degree of AS. 17, 18 Although larger sinus of Valsalva diameter was independently associated with larger aortic valve area also in multivariate analysis, no association was found with other measures of AS severity, including peak aortic jet velocity, mean transaortic gradient, and ELI, suggesting that the correlation with AVA mainly reflected the association between the aortic annular diameter and the sinus of Valsalva diameter. Including measurement of the sinus of Valsalva height is important in assessment of the feasibility for TAVI to avoid coronary ostial obstruction during prosthesis implantation. 4, 7, 8, 19, 20 The distance between the annulus and the sinotubular junction by computed tomography did not differ between patients with and without AS. 7 Covariates of the sinus of Valsalva height and the relation of height to width have not been reported in previous studies using TTE in AS patients. Thus, the present study adds to current knowledge by demonstrating that the sinus of Valsalva height was the most important covariate of the sinus of Valsalva diameter. Although smaller body size was associated with smaller sinus of Valsalva diameter independent of significant associations with gender, body size did not independently influence the sinus of Valsalva height. Interestingly, the sinus diameter was the duplication of its height. The previously published independent association of age with aortic root diameters in the normal population was not found in the present study. 16 In clinical practice, measurement of the sinus height by TTE may be used to indirectly reflect the level of the coronary ostia.
However, in most persons, the orifices of the coronary arteries arise within the two anterior sinuses of Valsalva, usually just below the sinotubular junction. 1,21 -23 Comparing measurements of aortic dimensions by transoesophageal and TTE have yielded excellent correlation without any significant difference, 6 but both methods underestimate aortic root diameters compared with multislice computer tomography. 2, 6, 7 Whether this also applies to measurement of sinus of the Valsalva height remains unknown. Still, TTE is recommended for assessment of TAVI feasibility.
In the current study, 61.9% of patients fulfilled vendor-specified requirements for aortic annular dimension to allow CoreValve and 66.9% to allow Edwards-Sapien valve implantation. The requirements for the sinus of Valsalva height were fulfilled in 66.8% to allow CoreValve implantation and in 91.4% to allow implantation of the shorter-framed Edwards-Sapien valve. The higher percentage of patients acceptable for Edwards-Sapien prostheses was particularly related to the acceptance of an at least 3 mm shorter sinus of Valsalva height. The overall percentage of patients acceptable for TAVI was 77.7% when any available prosthesis was taken into account and both required annular dimension and minimum sinus of Valsalva height were considered. The finding that more men than women met the current requirements for TAVI, both for the annular diameter and for the sinus of Valsalva height, reflects the smaller aortic root dimensions in women and relatively larger prosthetic sizes currently available. Of note, for choosing the appropriate prosthetic size, only assessment of the aortic annular dimension is currently absolutely required. 2, 3, 6, 19 Optimal preprocedural anatomic suitability assessment of the annulus diameter is essential for optimal prosthetic function and to avoid complications, such as aortic root trauma or post-procedural paravalvular leakage. 24 To prevent coronary obstruction, minimum sinus of Valsalva height requirements should be fulfilled, 8 in particular when the self-expanding longer CoreValve prosthesis is used. 5 The SEAS study included asymptomatic AS patients without diabetes, renal failure, predominantly aortic regurgitation, or coronary or peripheral artery disease and they represent a healthy AS patient population. Also a few patients with bicuspid aortic valves were recruited. Projection of the current findings into these patient categories should be done with caution. Of note a bicuspid valve is a relative contraindication to TAVI. According to guidelines, indication for TAVI is restricted to patients with major co-morbidities or other features which pose a substantial increased risk for conventional surgery. However, experience with TAVI has increased and, since the first-in-man TAVI by Alain Cribier 25 
